Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy.
Gadadhar
Harsha
H
Department of Medicine, University of Tennessee, College of Medicine-Chattanooga Unit, 975 East Third Street, Chattanooga, TN 37403, USA. drgadadhar@yahoo.com
Hawkins
Stephen
S
Huffstutter
J Eugene
JE
Panda
Mukta
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001706:Biopsy; D003881:Dermatomycoses / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D020091:Entomophthorales / Q000302:isolation & purification; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009091:Mucormycosis / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology; D011241:Prednisone / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000382:microbiology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D011241:Prednisone; D008727:Methotrexate